Clinical Trial Update: Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029) [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics and antiviral RNA data for vaniprevir (MK-7009) in chronic hepatitis C infection; study terminated with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• vaniprevir (vaniprevir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chronic Hepatitis C Infection | Phase 1 | Status: TERMINATED | Results posted: 2014-09-29